Skip to main content
Premium Trial:

Request an Annual Quote

Funding Access Remains

As part of a deal reached between the UK and the European Union, researchers in the UK will be able to receive EU research funding, according to ScienceInsider.

Days before the deadline, the UK and EU have negotiated a trade deal in the wake of the UK's departure from the EU after months of back-and-forth, BBC News reports. Scientists had particularly been worried about how leaving the EU might affect UK research funding — especially if there were to be a no-deal Brexit — and whether UK scientists could participate in the upcoming Horizon Europe funding program. UK researchers were among the top recipients of funding from Horizon Europe's predecessor, Horizon 2020, as Nature News reported last week.

Within the deal's 1,246 pages, ScienceInsider reports there is a provision that allows the UK to participate in Horizon Europe if it contributes to the EU budget. It notes that non-EU countries can pay association fees to become eligible to apply for EU research funding, as Switzerland and Israel have. There had been concerns, it adds, that the fees might be too steep for the UK to accept.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.